Avectas is a cell engineering company that has pioneered – SOLUPORE® – a cell engineering technology platform enabling the manufacture of next-generation cell therapy products. It is differentiated from the competition by the quality of modified cells including their viability, functionality and proliferation. The platform comprises a novel physicochemical transfection system, enabling complex gene editing in a GMP-aligned process.
Avectas is a private, international company with research facilities in Dublin, as well as an office in Cambridge MA, USA. It has over 30 employees and is led by a team of highly experienced pharmaceutical executives, who are supported by a world-class Scientific Advisory Board of cancer cell therapy experts. The Company has raised over US$50m to date.